Clinical Application of Plasmid-Based Cancer Vaccines

Dominick L. Auci, Denise L. Cecil, Daniel Herendeen, Elizabeth K. Broussard, John B. Liao, Gregory E. Holt, Mary L. Disis

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Decades of work on DNA-based cancer vaccination has produced numerous clinical candidates, most targeting single tumor-associated antigens, a few targeting multiple antigens or epitopes, and virtually all predominantly aimed at the induction of CD8+ cytotoxic T cells. Clinical trials in melanoma, prostate, breast, colorectal, and cervical carcinomas reporting results in the past few years are herein reviewed. Clinical and immunological responses were generally small and detected in only a minority of patients. High doses, extended immunization periods, and multifaceted platforms have modestly improved immunogenicity. Appreciating the important role polyfunctional CD4+ helper T cells play in tumor rejection, and using recent advances in epitope mapping and informatics, a new generation of DNA-based vaccines targeting CD4+ epitopes that are both tumor reactive and bind multiple MHC class II haplotypes are now entering clinical trials. With such an empirical approach, DNA-based vaccines may be poised to become potent weapons in the armamentarium against cancer.

Original languageEnglish (US)
Title of host publicationGene Therapy of Cancer
Subtitle of host publicationTranslational Approaches from Preclinical Studies to Clinical Implementation: Third Edition
PublisherElsevier Inc.
Number of pages9
ISBN (Print)9780123942951
StatePublished - Aug 2013
Externally publishedYes


  • Cancer clinical trials
  • DNA
  • Plasmid
  • Vaccine

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)


Dive into the research topics of 'Clinical Application of Plasmid-Based Cancer Vaccines'. Together they form a unique fingerprint.

Cite this